Publications by authors named "Barry Weatherley"

Claim this Profile
I
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Becky Jubb, Marilyn Lewis, Lynn McFadyen, Paul Simpson, Julie Mori, Barry Weatherley

Antivir Chem Chemother· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.
Barry Weatherley, Lynn McFadyen, Brinda Tammara

Clin Transl Sci· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose pharmacokinetics, safety, and tolerability of modified-release formulations of lersivirine in healthy subjects.
Manoli Vourvahis, Ronnie Wang, Laure Mendes da Costa, Cunshan Wang, Barry Weatherley

Clin Pharmacol Drug Dev· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.
K J Cortez, M A Proschan, L Barrett, D G Brust, Barry Weatherley

HIV Clin Trials· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Manoli Vourvahis, Juanzhi Fang, Tina Checchio, Ashley Milton, Barry Weatherley

HIV Clin Trials· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Phylinda L S Chan, Philippe Jacqmin, Marc Lavielle, Lynn McFadyen, Barry Weatherley

J Pharmacokinet Pharmacodyn· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.
Barry Weatherley, Lynn McFadyen

Br J Clin Pharmacol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Phylinda L S Chan, Barry Weatherley, Lynn McFadyen

Br J Clin Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis